
Andrea Spallanzani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/935861/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	New Horizons for Personalised Treatment in Gastroesophageal Cancer. Journal of Clinical Medicine, 2022, 11, 311.	2.4	3
2	Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy. Cancer Management and Research, 2022, Volume 14, 983-993.	1.9	0
3	Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study. Expert Review of Gastroenterology and Hepatology, 2022, 16, 73-79.	3.0	3
4	Multicentre match-paired analysis of advanced biliary cancer long-term survivors: The BILONG study. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101955.	1.5	1
5	Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience. Future Oncology, 2022, 18, 2651-2659.	2.4	0
6	Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers, 2021, 13, 1304.	3.7	2
7	The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center. Journal of Clinical Medicine, 2021, 10, 1705.	2.4	6
8	Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial. European Journal of Cancer, 2021, 148, 422-429.	2.8	8
9	Tremellmumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers, 2021, 13, 2839.	3.7	31
10	The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2021, 150, 155-167.	2.8	45
11	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). Journal of Clinical Oncology, 2021, 39, 2304-2312.	1.6	49
12	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Lifeâ€, Case-Control Study. Clinical Colorectal Cancer, 2021, , .	2.3	8
13	Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board. Nutrients, 2021, 13, 3522.	4.1	22
14	TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. American Journal of Cancer Research, 2021, 11, 4500-4514.	1.4	0
15	Magnetic resonance imaging performed before and after preoperative chemoradiotherapy in rectal cancer: predictive factors of recurrence and prognostic significance of MR-detected extramural venous invasion. Abdominal Radiology, 2020, 45, 2941-2949.	2.1	23
16	The prognostic nutritional index predicts survival and response to firstâ€line chemotherapy in advanced biliary cancer. Liver International, 2020, 40, 704-711.	3.9	42
17	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Oncologist, 2020, 25, 803-809.	3.7	26
18	mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus. Cancers, 2020, 12, 1201.	3.7	6

ANDREA SPALLANZANI

#	Article	IF	CITATIONS
19	Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. Clinical Colorectal Cancer, 2020, 19, 82-90.e9.	2.3	6
20	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist, 2020, 25, 481-487.	3.7	77
21	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. Oncologist, 2020, 25, 259-265.	3.7	27
22	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. Cancers, 2020, 12, 1022.	3.7	16
23	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. Oncologist, 2020, 25, 780-786.	3.7	14
24	Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update Journal of Clinical Oncology, 2020, 38, 11-11.	1.6	46
25	Synchronous and metachronous colorectal liver metastases: impact of primary tumor location on patterns of recurrence and survival after hepatic resection. Acta Biomedica, 2020, 92, e2021061.	0.3	0
26	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the â€~BRAF BeCool' study. European Journal of Cancer, 2019, 118, 121-130.	2.8	51
27	The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. European Journal of Cancer, 2019, 117, 84-90.	2.8	21
28	BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. International Journal of Molecular Sciences, 2019, 20, 5369.	4.1	88
29	Cannonball-Like Lung Nodules in a Patient With a Colorectal Tumor. Chest, 2019, 156, e85-e89.	0.8	2
30	<p>Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal CancerÂ(ITACa) study</p> . Cancer Management and Research, 2019, Volume 11, 4357-4369.	1.9	17
31	The treatment of rectal cancer with synchronous liver metastases: A matter of strategy. Critical Reviews in Oncology/Hematology, 2019, 139, 91-95.	4.4	9
32	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. BMC Cancer, 2019, 19, 283.	2.6	12
33	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist, 2019, 24, 185-192.	3.7	89
34	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. European Journal of Surgical Oncology, 2019, 45, 1479-1482.	1.0	10
35	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. European Journal of Endocrinology, 2019, 181, 681-689.	3.7	30
36	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 2018, 18, 198-203.	1.1	18

#	Article	IF	CITATIONS
37	Histopathological variables in liver metastases of patients with stage IV colorectal cancer: potential prognostic relevance of poorly differentiated clusters. Human Pathology, 2018, 78, 115-124.	2.0	13
38	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. Targeted Oncology, 2018, 13, 227-234.	3.6	33
39	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine, 2018, 60, 490-498.	2.3	59
40	To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer. Critical Reviews in Oncology/Hematology, 2018, 132, 154-160.	4.4	5
41	Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 1069-1076.	2.4	25
42	Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient. Gastrointestinal Tumors, 2018, 5, 14-20.	0.7	6
43	Immunotherapy in the treatment of colorectal cancer: a new kid on the block. Journal of Cancer Metastasis and Treatment, 2018, 4, 28.	0.8	7
44	A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study). Clinical Colorectal Cancer, 2017, 16, 410-415.e1.	2.3	7
45	The evolving role of microsatellite instability in colorectal cancer: A review. Cancer Treatment Reviews, 2016, 51, 19-26.	7.7	207
46	The somatic affairs of <i>BRAF</i> : tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. Journal of Clinical Pathology, 2013, 66, 441-445.	2.0	21